The Market Reports

Synopsis
The global market for Human Milk Oligosaccharides (HMO) was estimated to be worth US$ 708 million in 2024 and is forecast to a readjusted size of US$ 3225 million by 2031 with a CAGR of 24.6% during the forecast period 2025-2031.
Human Milk Oligosaccharides (HMO) are a class of complex carbohydrates naturally found in human breast milk. They are composed of multiple sugar units linked by glycosidic bonds. HMOs are one of the most abundant components in human milk after fat, protein, and lactose, and their concentration is significantly higher in human milk compared to other mammals. HMOs play a crucial role in infant health, serving as prebiotics that promote the growth of beneficial bacteria, such as bifidobacteria, helping to establish a healthy gut microbiome and enhance immune system function.
HMOs vary in structure, including monosaccharides, disaccharides, trisaccharides, and longer polysaccharide chains. Different types of HMOs have distinct biological functions, helping to combat pathogen invasion, reduce inflammation, and support brain development. While HMOs are primarily found in human milk, advances in technology have made it possible to extract and synthesize these oligosaccharides through fermentation and chemical processes for use in commercial products like infant formula, functional foods, and health supplements.
With ongoing research into the benefits of HMOs in infant health and other wellness applications, the demand for human milk oligosaccharides has been steadily increasing, particularly in infant formula and adult prebiotic foods.
Market Development Opportunities and Key Drivers:
As consumer awareness of health increases, especially in regard to infant health, the market for human milk oligosaccharides (HMOs) is experiencing significant growth opportunities. In recent years, extensive research on the role of HMOs in infant health has led more infant formula manufacturers to incorporate HMOs into their products to support immune function and gut health. Additionally, HMOs have shown potential in adult health applications, particularly in maintaining gut microbiome balance and enhancing immune function, opening new growth avenues for the market. As the global population ages and the demand for functional foods rises, there is also growing demand for prebiotic products targeting adults.
Market Risks:
Despite the promising outlook for the HMO market, there are several risks. First, the production of HMOs is complex and costly, which may hinder product accessibility and price competitiveness. Second, the HMO supply chain is intricate, involving multiple stages such as raw material extraction and fermentation. Any technological challenges or disruptions in production could affect the stability of the entire supply chain. Moreover, global regulatory and standard differences may pose challenges to market expansion, particularly in terms of varying regulatory policies and certification requirements in different countries.
Market Concentration:
Currently, the HMO production market is relatively concentrated, with several leading biotech and pharmaceutical companies dominating the industry. These companies have advanced fermentation and biosynthesis technologies that enable large-scale production while maintaining high quality. However, as technology advances and the market expands, more small and medium-sized enterprises are expected to enter the market, fostering competition and innovation.
Downstream Demand Trends:
The downstream demand for HMOs is mainly concentrated in infant formula, prebiotic foods and supplements, and personalized nutrition products. As consumers increasingly demand personalized and functional nutrition products, the market for HMOs as a functional ingredient will continue to grow. Additionally, the potential for HMOs in aging populations is being recognized, particularly for supporting gut health and immune systems in elderly individuals.
Latest Technologies:
The production technology for HMOs is continually evolving, with innovations in fermentation and biosynthesis reducing production costs. Furthermore, the application of genetic engineering and synthetic biology has opened up possibilities for customized HMO production, allowing for optimized efficiency and yields through genetically modified microorganisms.
This report aims to provide a comprehensive presentation of the global market for Human Milk Oligosaccharides (HMO), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Human Milk Oligosaccharides (HMO) by region & country, by Type, and by Application.
The Human Milk Oligosaccharides (HMO) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Milk Oligosaccharides (HMO).
Market Segmentation
By Company
Abbott
Inbiose
Glycom
Chr. Hansen (Jennewein)
Elicityl SA
ZuChem
Segment by Type
2'-FL & 3-FL
LNT & LNnT, etc.
Segment by Application
Infant Formula
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Milk Oligosaccharides (HMO) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Human Milk Oligosaccharides (HMO) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Human Milk Oligosaccharides (HMO) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index